Holen Sie sich die Stockscreener-App
30.80
0.42%
-0.0785
Schlusskurs vom Vortag:
$30.88
Offen:
$30.94
24-Stunden-Volumen:
4,146
Relative Volume:
0.28
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.92%
1M Leistung:
-9.37%
6M Leistung:
-5.76%
1J Leistung:
+15.49%
1-Tages-Spanne:
$30.69
$30.94
1-Wochen-Bereich:
$30.20
$32.09
52-Wochen-Spanne:
$26.38
$36.03
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile
Firmenname
Tema Etf Trust Tema Obesity Cardiometabolic Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie HRTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HRTS | 30.80 | 0 | 0 | 0 | 0 | 0.00 |
| VTI | 292.88 | 417.53B | 0 | 0 | 0 | 0.00 |
| SPY | 589.13 | 372.57B | 0 | 0 | 0 | 0.00 |
| IVV | 591.98 | 253.41B | 0 | 0 | 0 | 0.00 |
| VB | 252.01 | 160.59B | 0 | 0 | 0 | 0.00 |
| QQQ | 499.77 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Etf Trust Tema Obesity Cardiometabolic Etf Aktie (HRTS) Neueste Nachrichten
Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Yahoo Finance
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
(HRTS) Proactive Strategies - Stock Traders Daily
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' - Benzinga
Tema Endowment ETF plans to ride Wall Street’s private-asset craze - Pensions & Investments
Stone Ridge 2060 Inflation Protected Longevity Income ETF (LIAU) Chart and Price History 2024 - MarketBeat
An Endowment ETF Plans to Ride Wall Street’s Private-Asset Craze - Bloomberg
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Shares Up 0.1% - Defense World
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
HRTS: Generating Alpha In Obesity Treatment (NASDAQ:HRTS) - Seeking Alpha
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside - Seeking Alpha
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Benzinga
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say 'No' - Bloomberg
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Stock Price Down 1.1% - Defense World
Weight-loss drug forecasts jump to $150 billion as supply grows - The Business Standard
Watch Looking at Next Gen of Weight Loss: Tema ETFs CEO - Bloomberg
Spot Ether ETF: a Crypto Game Changer? - Opto RoW
ETFs to Profit from the Weight Loss Drug Boom - Yahoo Finance
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Investing in the diabesity epidemic: a breakthrough moment - Opto RoW
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
Thematic ETF Winners of the Q1 2024 Earnings Season - ETF Trends
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
The Impact of Bitcoin Halving on Investors and ETFs to Explore - The Globe and Mail
A New Horizon: Horizons ETF Management Canada to rebrand as Global X - The Globe and Mail
The 5 Best Biotech ETFs of 2024 - etf.com
Webcast: How to Invest in the Weight Loss Drug Revolution - ETF Trends
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss - Investor's Business Daily
'Continued innovation' is key when investing in weight loss trend - Yahoo Finance
Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space - Investor's Business Daily
The Truth HRTSETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet
US ETF launches from 16th to 23rd November, 2023 - ETF Express
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade - MarketWatch
New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - BNN Bloomberg
Be Thankful — It Could Have Been So Much Worse - Bloomberg
Finanzdaten der Tema Etf Trust Tema Obesity Cardiometabolic Etf-Aktie (HRTS)
Es liegen keine Finanzdaten für Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.21%
Kapitalisierung:
|
Volumen (24h):